French biopharma InnaVirVax closes €3.7m Series B

30

InnaVirVax, a French biopharmaceutical company that develops therapies for AIDS and HIV infection, has closed a €3.7m Series B financing round led by Pradeyrol Développement and private equity firms Fa Dièse and Fonds Régional de Co-Investissement Ile-de-France (FRCI).

InnaVirVax is dedicated to the development of therapeutic and diagnostic solutions in pathologies associated with immune dysregulation.

The funding will primarily enable the company to conduct phase I/IIa clinical trials of VAC-3S immunotherapy, it said.

Exising investors CapDecisif 2 and G1J Ile-de-France also participated in the round.

Copyright © 2012 AltAssets